Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
11.60
-0.14 (-1.19%)
At close: Feb 20, 2026, 4:00 PM EST
11.65
+0.05 (0.43%)
After-hours: Feb 20, 2026, 7:48 PM EST

Crescent Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024
Period Ending
Dec '24
Selling, General & Admin
12.63
Research & Development
56.14
Operating Expenses
68.76
Operating Income
-68.76
Interest Expense
-3.41
Interest & Investment Income
0.7
Pretax Income
-71.47
Net Income
-71.47
Net Income to Common
-71.47
Shares Outstanding (Basic)
5
Shares Outstanding (Diluted)
5
EPS (Basic)
-13.45
EPS (Diluted)
-13.45
EBIT
-68.76
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q